<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110032</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02651</org_study_id>
    <secondary_id>UPCC 01304</secondary_id>
    <secondary_id>CDR0000423313</secondary_id>
    <nct_id>NCT00110032</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors</brief_title>
  <official_title>Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects of fluorine F18 EF5 when given during
      positron emission tomography to find oxygen in tumor cells of patients who are undergoing
      surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18
      EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer
      treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the safety of fluorine F 18 EF5 (^18F-EF5) in patients with newly diagnosed
      brain tumors undergoing surgery or biopsy.

      Secondary I. Determine the pharmacokinetics and biodistribution of ^18F-EF5 administered
      before and after nonradioactive EF5 in these patients.

      II. Determine the ability of positron emission tomography (PET) scanning using ^18F-EF5 to
      detect tumor hypoxia in these patients.

      III. Determine the presence and pattern of nonradioactive EF5 binding by immunohistochemistry
      (IHC) and/or flow cytometry in these patients.

      IV. Correlate tumor hypoxia, as measured by PET scanning using ^18F-EF5, with EF5 staining by
      IHC and/or flow cytometry and recurrence-free survival of these patients.

      OUTLINE: Patients are assigned to 1 of 3 groups.

      Group 1: Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole
      body positron emission tomography (PET) scanning OR whole body PET scanning only. Patients
      then receive nonradioactive EF5 IV over 1-2 ½ hours.

      Group 2: Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV.
      Patients then undergo whole brain and whole body PET scanning.

      Group 3: Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then
      undergo whole brain PET scanning. Approximately one day after EF5 administration, all
      patients undergo surgery or biopsy of the tumor AND biopsy of normal skin adjacent to the
      incision.

      Patients are followed at 2-4 weeks and 4-6 weeks after EF5 administration and then every 3
      months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.
  </why_stopped>
  <start_date>June 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of F-18-EF5 based on the NCI CTCAE version 3.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Summarized in descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of radioactively labeled [F-18]-EF5</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of hypoxia, determined by [F-18]-EF5 PET imaging</measure>
    <time_frame>Up to day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IHC analysis of cold EF5</measure>
    <time_frame>Up to day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Central Nervous System Germ Cell Tumor</condition>
  <condition>Adult Choroid Plexus Tumor</condition>
  <condition>Adult Craniopharyngioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Ependymoblastoma</condition>
  <condition>Adult Ependymoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Grade I Meningioma</condition>
  <condition>Adult Grade II Meningioma</condition>
  <condition>Adult Grade III Meningioma</condition>
  <condition>Adult Medulloblastoma</condition>
  <condition>Adult Meningeal Hemangiopericytoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Myxopapillary Ependymoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Pineoblastoma</condition>
  <condition>Adult Pineocytoma</condition>
  <condition>Adult Subependymoma</condition>
  <condition>Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)</condition>
  <condition>Meningeal Melanocytoma</condition>
  <arm_group>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EF5</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>surgery, conventional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo PET</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorine F 18 EF5</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>18F-EF5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed and/or clinical and imaging evidence of a de novo mass that
             is likely to be a brain tumor

          -  Amenable to debulking surgery or surgical resection or biopsy as standard initial
             therapy for the tumor

          -  Performance status - Karnofsky 70-100%

          -  At least 3 months

          -  WBC count ≥ 2,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin &lt; 1.2 mg/dL

          -  Creatinine &lt; 1.3 mg/dL

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No other significant cardiac condition that would preclude study participation

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 1 month after study
             participation

          -  Weight ≤ 130 kg

          -  No peripheral neuropathy ≥ grade 3

          -  No history of allergic reaction attributed to metronidazole

          -  No other uncontrolled illness

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other medical condition that would preclude study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Michael Hahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Glioma, Subependymal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Etanidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

